Nanobiotix S.A. (NBTX) stock
NBTXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NNBXF
$27.45−1.09 (-3.82%)
Close on Nov 17, 2026Market cap $1.33BP/E –Yield –
Nanobiotix r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was €23.12M, down 43.0% from the year before. The highest annual figure on record is €40.54M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €23.12M | -43.0% |
| FY2024 | Dec 31, 2024 | €40.54M | +5.6% |
| FY2023 | Dec 31, 2023 | €38.40M | +17.6% |
| FY2022 | Dec 31, 2022 | €32.64M | +7.4% |
| FY2021 | Dec 31, 2021 | €30.38M | +24.9% |
| FY2020 | Dec 31, 2020 | €24.33M | -20.0% |
| FY2019 | Dec 31, 2019 | €30.41M | +45.6% |
| FY2018 | Dec 31, 2018 | €20.89M | – |
See a number that looks wrong?